Section Arrow
Quote
RGNT.NYSE-M
- Regentis Biomaterials Ltd.
Quotes are at least 15-min delayed:2025/09/16 23:16 EDT
Regular Hours
Last
 --
-- (--)
Day High 
-- 
Prev. Close
-- 
1-M High
-- 
Volume 
-- 
Bid
--
Ask
--
Day Low
-- 
Open
-- 
1-M Low
-- 
Market Cap 
-- 
Currency USD 
P/E -- 
%Yield -- 
10-SMA -- 
20-SMA -- 
50-SMA -- 
52-W High -- 
52-W Low -- 
Exchange NYSE-M 
Valuation Estimation
EPS (Current/Estimated)
0.96/--
Enterprise Value
--
Balance Sheet
Book Value Per Share
N/A
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
--
Operating Revenue Per Share
--
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
BNGOBionano Genomics Inc1.78-0.99-35.74%0.02PE
HBIOHarvard Bioscience0.4849+0.0454+10.33%-- 
AVTRAvantor12.71+0.32+2.58%12.27PE
BAXBaxter International23.87+0.07+0.29%140.32PE
MBOTMicrobot Medical3.34-0.08-2.34%-- 
Quotes are at least 15-min delayed：2025/09/16 23:16 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
Regentis Biomaterials Ltd is a regenerative medicine company dedicated to developing tissue repair solutions that restore health and enhance the quality of life of patients. It is focused on orthopedic treatments using its Gelrin platform based on degradable hydrogel implants to regenerate damaged or diseased tissue (inflamed cartilage and bone tissue). Gelrin is a hydrogel matrix of polyethylene glycol diacrylate (a polymer involved in tissue engineering) and denatured fibrinogen (a biologically inactivated protein that normally has a role in blood clotting). Its product is GelrinC, a cell-free, off-the-shelf hydrogel that is cured into an implant in the knee for the treatment of painful injuries to articularknee cartilage.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.